Christian E Bryant
Overview
Explore the profile of Christian E Bryant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Favaloro J, Bryant C, Abadir E, Gardiner S, Yang S, King T, et al.
Haematologica
. 2024 Oct;
110(2):507-513.
PMID: 39363853
No abstract available.
2.
Ho P, Spencer A, Mollee P, Bryant C, Enjeti A, Horvath N, et al.
Clin Lymphoma Myeloma Leuk
. 2024 May;
24(8):543-552.e1.
PMID: 38702217
Background And Purpose: Renal impairment (RI) confers adverse prognosis in myeloma; its reversal and avoidance of dialysis are crucial. We investigated whether serum free light chain (SFLC) measurements can predict...
3.
Favaloro J, Bryant C, Abadir E, Gardiner S, Yang S, King T, et al.
Haematologica
. 2023 Oct;
109(4):1220-1232.
PMID: 37794800
Multiple myeloma (MM) is an incurable disease of the bone marrow (BM) characterized by the uncontrolled proliferation of neoplastic plasma cells. While CD8+ T cells have an established role in...
4.
Rees M, Wu S, Mokoonlall M, Dix C, Bryant C, DRozario J, et al.
Leuk Lymphoma
. 2021 Apr;
62(10):2531-2534.
PMID: 33899667
No abstract available.
5.
Joshua D, Vuckovic S, Favaloro J, Lau K, Yang S, Bryant C, et al.
Front Immunol
. 2021 Mar;
12:620596.
PMID: 33708212
The classical paradigm of host-tumor interaction, i.e. elimination, equilibrium, and escape (EEE), is reflected in the clinical behavior of myeloma which progresses from the premalignant condition, Monoclonal Gammopathy of Unknown...
6.
Vuckovic S, Bryant C, Lau K, Yang S, Favaloro J, McGuire H, et al.
Blood Adv
. 2020 Sep;
4(19):4593-4604.
PMID: 32986791
CD8+CD57+ terminal effector T (TTE) cells are a component of marrow-infiltrating lymphocytes and may contribute to the altered immune responses in multiple myeloma (MM) patients. We analyzed TTE cells in...
7.
Li Z, Abadir E, Lee K, Clarke C, Bryant C, Cooper W, et al.
Clin Transl Immunology
. 2020 Jul;
9(7):e1156.
PMID: 32685149
Objectives: Effective antibody-drug conjugates (ADCs) provide potent targeted cancer therapies. CD83 is expressed on activated immune cells including B cells and is a therapeutic target for Hodgkin lymphoma. Our objective...
8.
Abadir E, Silveira P, Gasiorowski R, Ramesh M, Romano A, Mekkawy A, et al.
Blood Adv
. 2020 Mar;
4(7):1206-1216.
PMID: 32215656
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) significantly reduces the rate of relapse in acute myeloid leukemia (AML) but comes at the cost of significant treatment-related mortality. Despite the reduction in...
9.
Fromm P, Silveira P, Hsu J, Papadimitrious M, Lo T, Ju X, et al.
J Leukoc Biol
. 2019 Nov;
107(2):323-339.
PMID: 31749181
Myeloid lineage cells present in human peripheral blood include dendritic cells (DC) and monocytes. The DC are identified phenotypically as HLA-DR cells that lack major cell surface lineage markers for...
10.
Hsu J, Bryant C, Papadimitrious M, Kong B, Gasiorowski R, Orellana D, et al.
Oncoimmunology
. 2018 Apr;
7(4):e1419114.
PMID: 29632738
Only modest advances in AML therapy have occurred in the past decade and relapse due to residual disease remains the major challenge. The potential of the immune system to address...